Literature DB >> 1839040

Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis.

J Lima1, V Fonollosa, J Fernández-Cortijo, J Ordi, R Cuenca, M A Khamashta, M Vilardell, C P Simeón, M Picó.   

Abstract

The presence of anticardiolipin antibodies (aCL), von Willebrand factor activity and platelet function was studied in 35 patients with systemic sclerosis (SSc) scleroderma and 22 healthy controls. aCL positivity was observed in no patient with SSc or controls, whereas beta-thromboglobulin and platelet factor 4 levels were significantly higher in patients with SSc (p less than 0.001 and p less than 0.002, respectively). Furthermore, plasma from patients with SSc had a greater degree of aggregation to adenosine diphosphate 1 microM (p less than 0.05) but not to collagen or arachidonic acid. The plasma of patients with scleroderma also had increased von Willebrand factor activity compared with controls (p less than 0.001). We conclude that aCL appears not to play a central role in the pathogenesis of vascular and hemostatic alterations in SSc.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839040

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Microvascular involvement in systemic sclerosis and systemic lupus erythematosus.

Authors:  Didem Saygin; Kristin B Highland; Adriano R Tonelli
Journal:  Microcirculation       Date:  2019-04       Impact factor: 2.628

2.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

3.  Atypical presentation of scleroderma in infancy.

Authors:  Navin Mishra; Devendra Shrestha; Rakesh Babu Poudyal; K C Shiva Raj
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631

4.  Clinical significance of antiphospholipid antibodies in Indian scleroderma patients.

Authors:  R Gupta; M M Thabah; S Gupta; S Shankar; A Kumar
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

5.  Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis.

Authors:  Ewa Wielosz; Magdalena Dryglewska; Maria Majdan
Journal:  Clin Rheumatol       Date:  2009-05-13       Impact factor: 2.980

Review 6.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

7.  Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis.

Authors:  Vincent Sobanski; Angélique Lemaire-Olivier; Jonathan Giovannelli; Luc Dauchet; Myriam Simon; Benjamin Lopez; Cécile Yelnik; Marc Lambert; Pierre-Yves Hatron; Eric Hachulla; Sylvain Dubucquoi; David Launay
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

8.  Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study.

Authors:  Konstantinos Ntelis; Vasileios Gkizas; Alexandra Filippopoulou; Periclis Davlouros; Dimitrios Alexopoulos; Andrew P Andonopoulos; Dimitrios Daoussis
Journal:  BMC Musculoskelet Disord       Date:  2016-05-17       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.